| 5.1 Non‐biological treatments versus placebo |
2 |
283 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.67 [‐1.40, 0.06] |
| 5.1.1 Methotrexate versus placebo |
2 |
283 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.67 [‐1.40, 0.06] |
| 5.2 Non‐biological treatment 1 versus non‐biological treatment 2 |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 5.2.1 Methotrexate versus fumaric acid esters |
1 |
108 |
Mean Difference (IV, Fixed, 95% CI) |
‐7.44 [‐9.47, ‐5.41] |
| 5.3 Anti‐TNF alpha versus placebo |
25 |
8534 |
Std. Mean Difference (IV, Random, 95% CI) |
‐1.08 [‐1.19, ‐0.97] |
| 5.3.1 Etanercept versus placebo |
8 |
3246 |
Std. Mean Difference (IV, Random, 95% CI) |
‐1.11 [‐1.34, ‐0.88] |
| 5.3.2 Adalimumab versus placebo |
9 |
3055 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.98 [‐1.11, ‐0.85] |
| 5.3.3 Certolizumab versus placebo |
3 |
588 |
Std. Mean Difference (IV, Random, 95% CI) |
‐1.00 [‐1.26, ‐0.74] |
| 5.3.4 Infliximab versus placebo |
5 |
1645 |
Std. Mean Difference (IV, Random, 95% CI) |
‐1.29 [‐1.48, ‐1.10] |
| 5.4 Ustekinumab versus placebo |
9 |
3359 |
Std. Mean Difference (IV, Random, 95% CI) |
‐1.35 [‐1.54, ‐1.16] |
| 5.5 Anti‐IL17 versus placebo |
6 |
3566 |
Std. Mean Difference (IV, Random, 95% CI) |
‐1.46 [‐1.80, ‐1.13] |
| 5.5.1 Ixekizumab versus placebo |
3 |
3126 |
Std. Mean Difference (IV, Random, 95% CI) |
‐1.76 [‐2.09, ‐1.43] |
| 5.5.2 Brodalumab versus placebo |
2 |
349 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.96 [‐1.44, ‐0.47] |
| 5.5.3 Secukinumab versus placebo |
1 |
91 |
Std. Mean Difference (IV, Random, 95% CI) |
‐1.41 [‐1.87, ‐0.94] |
| 5.6 Anti‐IL23 versus placebo |
8 |
4146 |
Std. Mean Difference (IV, Random, 95% CI) |
‐1.46 [‐1.62, ‐1.30] |
| 5.6.1 Guselkumab versus placebo |
3 |
1444 |
Std. Mean Difference (IV, Random, 95% CI) |
‐1.36 [‐1.54, ‐1.18] |
| 5.6.2 Tildrakizumab versus placebo |
3 |
1904 |
Std. Mean Difference (IV, Random, 95% CI) |
‐1.36 [‐1.48, ‐1.23] |
| 5.6.3 Risankizumab versus placebo |
2 |
798 |
Std. Mean Difference (IV, Random, 95% CI) |
‐1.82 [‐2.04, ‐1.60] |
| 5.7 Biologic versus non‐biological treatment |
5 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 5.7.1 Adalimumab versus methotrexate |
1 |
218 |
Mean Difference (IV, Fixed, 95% CI) |
‐3.40 [‐5.75, ‐1.05] |
| 5.7.2 Ixekizumab versus fumaric acid esters |
1 |
108 |
Mean Difference (IV, Fixed, 95% CI) |
‐7.71 [‐9.74, ‐5.68] |
| 5.7.3 Ixekizumab versus methotrexate |
1 |
108 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.27 [‐2.31, 1.77] |
| 5.7.4 Guselkumab versus fumaric acid esters |
1 |
119 |
Mean Difference (IV, Fixed, 95% CI) |
‐5.80 [‐8.06, ‐3.54] |
| 5.7.5 Risankizumab versus fumaric acid esters |
1 |
120 |
Mean Difference (IV, Fixed, 95% CI) |
‐7.60 [‐9.97, ‐5.23] |
| 5.7.6 Brodalumab versus fumaric acid esters |
1 |
210 |
Mean Difference (IV, Fixed, 95% CI) |
‐2.57 [‐4.27, ‐0.87] |
| 5.8 Biologic 1 versus biologic 2 |
8 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 5.8.1 Ixekizumab versus etanercept |
2 |
2209 |
Mean Difference (IV, Fixed, 95% CI) |
‐1.99 [‐2.39, ‐1.59] |
| 5.8.2 Guselkumab versus adalimumab |
2 |
1407 |
Mean Difference (IV, Fixed, 95% CI) |
‐1.73 [‐2.50, ‐0.97] |
| 5.8.3 Risankizumab versus ustekinumab |
2 |
799 |
Mean Difference (IV, Fixed, 95% CI) |
‐1.00 [‐1.50, ‐0.50] |
| 5.8.4 Tildrakizumab versus etanercept |
1 |
932 |
Mean Difference (IV, Fixed, 95% CI) |
‐1.40 [‐2.20, ‐0.60] |
| 5.8.5 Infliximab versus etanercept |
1 |
48 |
Mean Difference (IV, Fixed, 95% CI) |
‐1.60 [‐2.93, ‐0.27] |
| 5.9 Small molecules versus placebo |
9 |
5061 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.79 [‐0.99, ‐0.60] |
| 5.9.1 Apremilast versus placebo |
5 |
2166 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.59 [‐0.70, ‐0.47] |
| 5.9.2 Tofacitinib versus placebo |
4 |
2895 |
Std. Mean Difference (IV, Random, 95% CI) |
‐1.08 [‐1.23, ‐0.93] |
| 5.10 Biologic versus small molecules |
1 |
|
Std. Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 5.10.1 Etanercept versus tofacitinib |
1 |
998 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.06 [‐0.19, 0.07] |
